Latest in Cardiology from ACC.org

• HHS Releases Consumer Alert on Fraudulent CV Testing Schemes
  The U.S. Department of Health and Human Services' (HHS') Office of Inspector General has issued a consumer alert, urging parents, caregivers, athletic programs and student athletes to beware of fraudulent cardiovascular testing schemes exploiting fears around sudden cardiac arrest in young athletes.
• Combined LDL-C, Lp(a) and hsCRP Assessment Identifies Long-Term Risk of ASCVD
  Combined assessment of LDL-C, Lp(a) and hsCRP reflected independent pathways for identifying individuals of varied ethnicities at greater long-term risk of atherosclerotic cardiovascular disease (ASCVD), according to an analysis of the HELIUS cohort published June 24 in JACC.
• 2026 Mid-Year Update on ACC Advocacy Efforts
  Throughout the first half of 2026, ACC’s Advocacy Team has been actively engaged in shaping policy at both the federal and state levels and working with policymakers to support cardiovascular clinicians and improve patient care nationwide. Read about key highlights from this work below.
• New Risk Score Helps Identify Bleeding Risk With DOACs in Cancer-Associated VTE
  The novel ONCO-DOAC BLEED risk score, developed by Tomoyuki Nagai, MD, et al., provided clinically relevant major bleeding risk stratification for patients with cancer-associated venous thromboembolism (VTE) receiving direct oral anticoagulants (DOAC), according to research published June 16 in JACC: CardioOncology.
• MAPLE-HCM Analysis: Aficamten Monotherapy Superior to Metoprolol in Combating Exercise Intolerance in oHCM
  Aficamten monotherapy was superior to metoprolol in promoting adaptation to multiple phases of exercise in patients with symptomatic obstructive HCM (oHCM), according to a prespecified analysis of the MAPLE-HCM trial published June 17 in JAMA Cardiology.